ATNF NASDAQ

1180 Life Sciences Corp. is a biotechnology firm currently in the clinical trial phase, dedicated to creating treatments for pressing medical challenges including chronic pain, inflammation, fibrosis, and other related inflammatory conditions. The company's therapeutic pipeline is supported by three primary development platforms: An anti-tumor necrosis factor (anti-TNF) and fibrosis platform is progressing through Phase IIb clinical trials, specifically targeting fibrosis and anti-TNF pathways. A Synthetic Cannabidiol (CBD) Analogs platform, featuring laboratory-created derivatives of CBD, is currently in preclinical development. An a7nAChR platform, which functions as an immune suppressive agent by focusing on the alpha 7 nicotinic acetylcholine receptor, is also undergoing preclinical evaluation. Established in 2016, 1180 Life Sciences Corp. is based in Palo Alto, California.